Reputation – MPs: Overview
Read more about the reputation of pharmaceutical companies operating in the UK among MPs
The COVID-19 response is reshaping how MPs regard pharmaceutical companies operating in the UK
What’s happened with COVID is I think some of these pharmaceutical companies have actually been pretty impressive in terms of the work they’ve done to get the vaccinations underway. And so, I’ve been, a bit more impressed with them than perhaps I was before, with their social responsibility and their understanding that obviously, they’re there to make money and profit but they also have responded very quickly to this new threat of COVID. I think I’ve been more impressed than I have been in the past. Labour Backbencher
MPs remain familiar with pharmaceutical companies operating in the UK, and the depth of familiarity has increased. A year ago half felt they knew at least a fair amount about the sector. Now, over six in ten do. However, whilst familiarity has increased year on year, the extent to which MPs are positive towards, trust or are likely to speak highly of the sector hasn’t changed to a significant degree.
Reputational strengths in last year’s index remain strengths today. MPs tend to associate the sector with innovation, R&D and global leadership.
Despite cost of living and economic uncertainty, COVID-19 remains a dominant concern (as of Feb 2022).
Share this chart: https://datawrapper.dwcdn.net/bw71z/1/
In this context, the sector’s reputation is in good shape; MPs generally agree that pharmaceutical companies in the UK make a positive contribution to society, and in particular the economy. For many MPs, this positive perspective is reinforced by their confidence in the sector’s ability to research and develop innovative, safe and effective medicines. Thus, these perspectives should help maintain the high level of goodwill the sector currently has in Westminster.
The response to COVID-19 continues to underpin overwhelmingly positive responses from MPs with even critics singing the sector’s praises. However, the source of their positivity is now shifting from the development of the vaccine to now focussing on the ongoing deployment of them.
Last modified: 20 September 2023
Last reviewed: 20 September 2023